Life Sciences Archive » March, 2019

Life Sciences - March, 2019

330 articles

• Impax Payment Was Meant To Dodge Competition, FTC Says
• J&J's 3-Deal Day Signals A Shift In Legal War Over Talc
• Monsanto's Split-Trial Gamble Backfired With $80M Verdict
• 7 Firms To Steer 4 IPOs Led By PE-Backed Trading Platform
• Mylan Gets Some Parts Of Investors' EpiPen Suit Trimmed
• Legal Bruises Add Up For Trump's Health Policy Vision
• Valeant Wants Ex-NJ AG Knocked Off Stock-Drop Suit
• Del. Jury Clears Teva In $41M Orexo Drug Patent Suit
• Pelvic Mesh MDL Fee Committee Accused Of Self-Dealing
• DOJ Seeks Toss Of Whistleblower's Gilead FCA Case
• Medtox Class Gets Initial OK Of $1.6M Deal In TCPA Suit
• Deal Could End Investor Suit Over Alleged $47M Withdrawal
• Court Ruling Won't Stop PTAB's Review Of Vimovo Patent
• $448M Win In AbbVie Case Not Enough, FTC Tells 3rd Circ.
• 8 Insys Docs Tallied $28M In Medicare Costs, Jury Hears
• CFIUS 2.0 Roundup: The Pilot Program, The Shoulder Shrug
• Alkermes Beats Investor Suit Over Opioid Addiction Treatment
• WilmerHale Hires Back Former SEC Commish From Mylan
• Feds Slam Pharma Execs' Bid To Void Kickback Convictions
• Fresenius To Pay $231M To Resolve Foreign Bribery Charges
• Medtronic Wants Full Fed. Circ. To Undo $24M Spine IP Loss
• 3rd Roundup Trial Begins Day After $80M Monsanto Loss
• Pharma Cos. Owe $30M For Acquired Drug's Gains, Suit Says
• 3 Fights The Fed. Circ. Picked With The PTAB In 2018
• Fed. Circ. Revives Opana Patent Axed As Natural Law
• Biotech Exec Gets 2 Years For Embezzlement
• FDA Needs New Opioid Standards, Gottlieb Tells Senators
• J&J Can't Get Pa. Mesh Mistrial Over Expert's Heart Attack
• No Nucynta Generics Until 2025, Fed. Circ. Affirms
• 2 Firms Lead Precision BioSciences' $126M IPO
• Murky Akrimax Fraud Case Gets Some Clarity At Chancery
• Sacklers Illegally Siphoned Opioid Profits, NY's AG Says
• Brexit Risk-Disclosure Considerations For US Reporting Cos.
• There's More To Cosmetics Regulation Than Meets The Eye
• Stryker To Bring On Johnson & Johnson Exec For CLO Spot
• Expectations For Glyphosate Litigation After Monsanto Verdict
• J&J Settles 2 Asbestos-In-Talc Cases Mid-Trial
• Lawmakers Aim To Abandon Courts' Forbidden Patent Types
• 'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics
• 5th Circ. Won't Make Becton Pay Out Profits Over False Ads
• Real Estate Rumors: Baywood Hotels, Calmwater, Fluidigm
• Fed. Circ. Judges You Wanted On Your PTAB Appeal In 2018
• Kimberly-Clark Beats Whistleblower Suit Over Medical Gowns
• Monsanto Hit With $80M Verdict In First Fed. Roundup Trial
• Insys Exec Flung Phone Off Mountain To Hide Info, Jury Hears
• 'This Emperor Clearly Has No Clothes': 2018 In Patent Dissent
• J&J Wins Another Asbestos-In-Talc Trial In NJ
• Cooley, Linklaters Steer Biopharma Genfit's $135M Debut
• Clinic's Parent Co. Can't Arbitrate Destroyed Embryo Claims
• Novartis Whistleblower Keeps $1.5M Award, Still Faces Probe
• Allergan Gets Shire's Dry-Eye Drug Antitrust Suit Dropped
• Cephalon, Mylan, Ranbaxy Ink Combined $65.8M Provigil Deal
• AbbVie Wants Suit Alleging Kickbacks, Buyback Scheme Axed
• FTC Extends Scrutiny Of Bristol-Myers' $74B Celgene Buy
• Drug Store Not Liable In Side Effect Suit: Ill. Appeals Court
• J&J Tells Jury Greedy Lawyers Driving Asbestos-In-Talc Fight
• Chancery OKs New Stay For 'Dark' Insys Derivative Claims
• 'Send Monsanto A Message,' Jury Told At Roundup Trial's End
• The Federal Circuit In 2018: A By-The-Numbers Snapshot
• Express Scripts Owes $14M In Tax, Wash. Appeals Court Says
• 3M Settles Dentists' Defective Crown Suit For $32.5M
• Is Purdue's $270M Deal Beginning Of End For Opioid Cases?
• PTAB Upholds Skin Cancer Detection Patent
• Chancery Says It Won't Keep Takeda's Foreign Patent Fight
• Ex-Insys Rep Recounts Ties, Some Physical, To Founder
• These Firms Crushed It At The Federal Circuit In 2018
• Walgreens, Kroger Cut From J&J's Remicade Antitrust Fight
• Urine Big Trouble: Willfulness, Misconduct Spark $3M IP Loss
• 2nd Circ. Refuses To Revive Complaints In Eliquis MDL
• Purdue To Pay $270M To End Oklahoma AG's Opioid Suit
• And Now A Word From The Panel: An MDL Denial
• 'Imperfect' Treatment Result Not J&J Mesh's Fault, Jury Told
• Setting The Record Straight On Women In Court Reporting
• Natera Infringing Transplant Testing Patents, Stanford Says
• J&J And Plaintiff Ask 'What Is Asbestos?' As Talc Trial Opens
• Tufts Hires Ex-US Atty To Review Purdue, Sackler Influence
• Myriad Genetics Ditches Medicare Overbilling Stock-Drop Suit
• Atty Privilege Forces Uneasy Judge To Limit 2 Insys Witnesses
• Cancer Researcher Says Center Must Pay Up For Treatments
• Faulty Mesh Worsened Woman's Incontinence, Pa. Jury Hears
• Analogic Beats DOL's Pay Discrimination Claims
• Ex-Monsanto CEO Defends Roundup, Concedes Study Limits
• Boston Scientific OK To Fire Worker After DUI, 3rd Circ. Says
• Hahn Loeser Forms Ill. Biometric Privacy Practice Group
• Philly Judge Won't Boot Colleague From J&J Mesh Dispute
• DePuy Alleges Rival Induced Workers To Break Contracts
• J&J Talc Source Lifts Del. Ch. 11 Stay For Past Owner
• $660M Biotech Co. Merger Offer Is Too Low, Investors Say
• Trading Platform, Med Device Biz Prime IPOs Totaling $757M
• Ex-Aveo CFO Gets 2-Year Corporate Bar For Duping Investors
• Limiting Supreme Court's Size Is Not Enough
• Bayer, Janssen Pay $775M To End Xarelto Suits
• J&J Can't Avoid Vote On Shareholder Arbitration, Suit Says
• Monsanto Jury Hears Cancer Changed Couple's Lives
• Pharma Co. Reaches $3.6M Deal With Unsecured Creditors
• AVX Seeks Redo Of Greatbatch's $22M Pacemaker Patent Win
• Medtronic Warning Highlights Debate On FDA Cyber Policy
• Lamictal Antitrust Class Action Paused For Certification Fight
• Employers Can't Keep Arbitrations Secret, NLRB Judge Says
• Meet The Outspoken Judge Handling Epic Monsanto Case
• Lyft's $2B IPO Dominates Week That Could See 4 Deals Price
• Small Changes To Old Drugs Don't Extend Patents, ECJ Says
• MabVax Hits Ch. 11, Blaming Alleged $27M Pump-And-Dump
• Anixa Directors Say Option Price, Patent News Not Related
• Attys' Fees Trimmed To $1.3M In Vertex Junk Fax Settlement
• VC-Backed Turning Point Files $100M Cooley-Led IPO
• Vt. Can Move Ahead With Opioid Suit Against Purdue Pharma
• Swiss Firm Takes French Biotech Co. Private For €730.1M
• Omnicare's $20M Settlement With Investors Gets Initial OK
• 17 Alleged Misstatements Cut From Dr. Reddy's Investor Suit
• What To Know About New FDA Commissioner Sharpless
• Sens. Seek Answers About Doctor-Owned Medical Suppliers
• 1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says
• Rejected J&J Job Seeker Must Arbitrate Claim, 3rd Circ. Told
• Firms Contest Class Counsel Bid In Trevena Investor Suit
• Lenders Score Major High Court Victory In Foreclosure Case
• Trial Counsel's Role On A Mass Tort Virtual Law Team
• Law360's Life Sciences Editorial Advisory Board
• Tech Trends From SXSW Pose Unique Questions For Lawyers
• Health Care IP Key To Cutting Costs: FTC Member
• What's In A Judgeship? More Than Meets The Eye
• Swamped: How Magistrate Judges Salvaged Louisiana's Judicial Crisis
• Full Fed. Circ. Won't Review Stryker's $254M Damages Win
• Pointed Questions Suggest Longer FCA Time Limit Is Likely
• Teva's 'Strategic Decision' On FCA Testimony Gets Judge's Ire
• J&J Talc Supplier's Ex-Owners Ask For Ch. 11 Shield
• Monsanto Jury Told $63B Co. Should Pay Up Over Roundup
• Workers Can Sue Labs For Shoddy Drug Tests: SC Justices
• Dental Supply Co. Must Face Price-Fixing Suit, Investors Say
• Real Estate Rumors: Morgan Stanley, AEW, Stockbridge
• CMS Looks To End Pharma Co.'s Drug Classification Suit
• Insys Founder's Atty Seeks Mistrial Over Addiction Testimony
• Roche Accuses Health Co. Execs Of $87M Test Strip Fraud
• Testosterone Supplement Damaged Pa. Man's Liver, Suit Says
• Justices' Input Needed In ERISA Preemption Fight, Ark. Says
• In Bar Admissions Process, It's Candor Or Bust
• Off-Label Promotion Still A Litigation Risk For Pharma Cos.
• BakerHostetler DQ'd From Opioid MDL Bellwethers
• Allergan Urges Justices To Hear PTAB Tribal Immunity Suit
• J&J Talc Supplier Tort Claimants Fight Insurance Fund Bid
• 'In A Timely Manner': Three Decades Of Judgeship Bills
• From Showdowns To Hotlines, Frazzled Judges Get Creative
• Kaplan Fox Wins Lead In MiMedx 'Channel-Stuffing' Suit
• Abbott Must Face Analyst's Bias Claim, Illinois Panel Says
• Athenex Says FDA Wrongly Policing Practice Of Medicine
• Insys Opioid Prescriber Was Addicted Himself, Witness Says
• Asia, Huawei Dominating International Patents, WIPO Says
• Puma Biotech Owes $22M For Libel In Proxy Fight, Jury Says
• Justices Ponder FCA Ambiguities In Time Limit Case
• Monsanto's Roundup Likely Caused Cancer, Calif. Jury Says
• Justices Offer Practical Approach To Class Appeal Deadline
• Judging A Book: Bashant Reviews 'Doing Justice'
• AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'
• Sanctions Sought Over Appeal In Synergy Pharma's Ch. 11
• Willkie Nabs Cooley Deals Pro In Silicon Valley
• These Are The Nation's 27 Most Overworked District Courts
• As Judicial Ranks Stagnate, 'Desperation' Hits The Bench
• Fed. Circ. Rejects $750K Award Over Soured Med Device Deal
• Mesh Victims Slam J&J's 'Judge-Shopping' In Pa. Recusal Bid
• Ohio Sues OptumRx To Collect $16M In Alleged Overcharges
• Novartis Eye Care Unit Buys PowerVision for $285M
• 3rd Circ. To Hear Class Cert. Appeal In Lamictal Case
• NC Gene Editing Co. Launches IPO That Could Raise $134M
• If There, Then Here: How Gov't Probes Help Antitrust Plaintiffs
• High Court Won't Take Post-Escobar FCA Materiality Case
• Firms Can Leverage Communications When Economy Is Slow
• Justices Consult SG On Treatment Patent Case Testing Mayo
• Bipartisan Bill Eyes Drug Imports To Boost Competition
• Novartis Aims To Sink 'Inconsistent' Whistleblower Verdict
• OvaScience Investor Seeks Cert. In IVF Treatment Suit
• Purdue Says Cameras Will Turn Opioid Trial Into 'Media Circus'
• Health Hires: Baker McKenzie, Alston & Bird
• Medical Device Co. Hit With Investor Action Over Sale
• Pfizer, Hospira Beat FCA Suit Over Faulty Infusion Pumps
• Fed. Circ. Clarifies Alice In Reviving Supplement Co.'s IP Suit
• Insys Exec Denied Mistrial Bid After 'Salacious' Testimony
• Fetal Tissue Law Fight Belongs In State Court, 7th Circ. Says
• Hikma V. Vanda Exaggerates Treatments' Patent Eligibility
• Fed. Circ. Wants Redo For IP Suit Over Allergan Antipsychotic
• Bayer Must Face Essure Stillbirth Suit, 4th Circ. Rules
• Fed. Circ. Wary Of Ruling On AIA Patent Challenge Meaning
• Merck Antitrust Scheme Didn't Work, UK Says, Ending Probe
• US Trustee Challenges TridentUSA's Ch. 11 Bid For Bonuses
• Delaware Bill Seeks Fee On Opioid Makers Amid Health Crisis
• Monsanto Must Face Couple's Claims At One Trial: Judge
• Stryker Buys Israeli Med Tech Co. In Deal Worth Up To $220M
• Insurers Fight J&J Talc Co.'s Insurance Pay Plan, Claim Rep
• 4 Firms Lead French Biotech Genfit's Estimated $132M IPO
• Penny Stock CEO Can't Slip SEC Suit Over Deceptive Promos
• Investors Fight Keryx Bid To Ditch Kidney Drug Stock Case
• The Future Of The USMCA: 3 Possible Scenarios
• Attys In Opioid Suits Are Holding Big Pharma Accountable
• Ethical Social Media Marketing For Lawyers
• A Chat With Norton Rose Diversity Director Nina Godiwalla
• Litigation Worries Loom As House Mulls Drug-Pricing Bills
• Retrial Jury Hears J&J Mesh Not To Blame For Woman's Pain
• J&J Hit With $29.5M Verdict In Latest Talc Trial
• Claire's Hit With Suit A Day After Asbestos Makeup Recall
• Final Guilty Pleas End Case Of Misbranded Supplements: DOJ
• Bio-Rad Asks 9th Circ. To Rethink Ex-GC's $8M Win
• Pharma Co. Pumped Stock By Hiding Drug Failures, Suit Says
• Insys' $25M Legal Tab For Founder Adds To Its Hazy Future
• Allergan Says It Needs Takeda Docs To Fend Off NJ Suit
• Merck Gets PTAB To Nix Pfizer Vaccine Patent
• Monsanto Bellwether Over Roundup Cancer Risk Goes To Jury
• Deals Rumor Mill: BioNTech, HNA, Malaysia Airlines
• Glancy Prongay Seeks To Lead Nerve-Repair Co. Investor Suit
• Generic-Drug Exclusivity 'Squatting' Draws Bipartisan Heat
• Perrigo Wins $2M In Damages In Flea And Tick Product Row
• Sterigenics Emissions Suit Remanded To State Court
• Pa. Justices Won't Boot Philly Judge From Mesh Trial
• 'Tell The Truth Or Lose Your Soul' Threat Spurs Sanctions Bid
• Synergy Pharma Gets OK For Ch. 11 Plan Releases
• Talc Use Increases Risk Of Ovarian Cancer, Lawmakers Told
• Bernstein Litowitz Seeks $13M In Atty Fees In Medtronic Case
• Paul Weiss, Hogan Steer $660M Deal For Regenerative Med Biz
• 5 Mistakes Law Firms Make When Responding To RFPs
• Fujifilm Pays $890M For Biogen Biologic Manufacturing Site
• Oncologist Testifies Roundup's Link To Cancer Lacks Proof
• J&J Tells Jury It Got 'Out-Lawyered' In Talc Trial
• BakerHostetler, Takeda Unit Dodge Suit Over Voided Patent
• Pfizer To Pay $1M Over Deceptive Drug Coupons In Ore. Deal
• Doctor's Trial Win Doesn't Make DEA's Arrest Wrong: Judge
• Sinovac's Poison Pill Attempt Stalled By Del., Antigua Courts
• Asacol 3rd-Party Payors Want Another Shot At Class Cert.
• Medicare Insider Trading Case Beset By Flaws, 2nd Circ. Told
• Valeant Conflict Wasn't A Crime, Ex-Execs Tell 2nd Circ.
• USPTO Patent Eligibility Rules Still Too Vague, IP Groups Say
• Synthetic Capsule Patent App Fails, Fed. Circ. Says
• Takeaways From FDA's New Bulk Drug Substance Restrictions
• 2nd Circ. Revives Needle-Phobic Walmart Worker's Suit
• Senate Patent Bill To Boost Biosimilars Needs Work, Attys Say
• Feds To Probe Shkreli Using Cellphone To Run Biz From Jail
• Takeda Unit Fights $155M IP Loss, Bayer Wants $27M More
• 4th Circ. Won't Rethink $87M Heparin Suit Coverage Win
• Fed. Circ. Dismisses Moot Appeal Over Opana ER Patents
• Spark's $4.8B Sale To Roche Is 'Unfair,' Investor Claims
• J&J Talc Supplier's Ex-Owners Can't Tap Insurance Funds
• FDA To Quiz Prescribers On Opioid Promotion
• J&J Wants Philly Judge Booted From Further Mesh Trials
• Claire's Makeup Dust-Up Shows Limits Of FDA Oversight
• Health Hires: Quarles & Brady, Reed Smith, Post & Schell
• Taxation With Representation: Skadden, Sullivan, Simpson
• Walgreens Must Face Whistleblower's FCA Suit Over $4 Drugs
• 9th Circ. Gives Costco False Ad Suit Another Shot
• How SEC Could Expand 'Test The Waters' Communications
• Wadler V. Bio-Rad Poses Noteworthy Whistleblower Questions
• J&J Talc Supplier Sues Over Millions In Insurance Funds
• Bill Fighting Pharma Delay Tactics Wins Bipartisan Backing
• Bayer Must Face Suit Over Flintstones 'Complete' Vitamins
• Ex-Insys VP Defiant During Cross-Examination At RICO Trial
• All Biosimilars Will Get Special Names, FDA Says
• Leon Panetta In The Courtroom, Langley And Area 51
• Davis Polk-Led Medical Device Biz Debuts With $97M IPO
• Ex-Pharma Sales Rep Gets 4 Years For $3.5M Rx Scheme
• Chinese Biotech Co. Pulls Back Suit Over Biased H-1B Denials
• Kratom Death Should Spur Gov't Into Action, Pa. Family Says
• Justices Urged To Turn Down PTAB Tribal Immunity Case
• Texas Supplements Co. To Close, Pay $4.7M In Plea Deal
• Gottlieb Leaves Vocal Legacy At FDA
• Hospira Tells Fed. Circ. To Reverse Sedative Patent Loss
• TridentUSA Authorized To Fully Tap $50M Ch. 11 DIP Loan
• Insys CEO Demanded Loyalty Over Integrity, Ex-VP Testifies
• FCA Claim Rightly Axed In $70M Kickback Suit, Judge Says
• Concerns Raised Over Credit Bid In Novum Pharma's Ch. 11
• Copyright Ruling Could Hinder USPTO's High Court Fee Case
• Abbott Ruling Dulls Insurers' 'Knowing Violation' Sword
• Horizon Pharma Facing DOJ Probe Into PBM Payments
• GSK's Avandia Marketing Was Racketeering, 3rd Circ. Told
• Fed. Circ. Won't Revisit Restasis Patent Ruling
• Why I Became A Lawyer: Finding A Voice, And A New Home
• CORRECTED: Novartis Wants Janssen Barred From Disparaging Rival Drug
• Mintz Fraade Says Embattled Biotech's Insurer Owes Bills
• Pa. Justices Will Hear Suit Alleging Cancer-Pesticide Link
• Bristol-Myers Urges Investors To Back $74B Celgene Buy
• Beam Therapeutics Snags $135M In Latest Funding Round
• Aralez Ch. 11 Sale Of Toprol Brand To Deerfield Approved
• DQ Threat In Opioid MDL Could Steer Attys From Public Work
• Endo Wants Perrigo's B12 Nasal Spray Generic Blocked
• Gov't Urged Not To Break Patents To Lower Drug Prices
• 2 Firms Steer Pacira's $220M Medical Device Co. Buy
• Illumina Tells PTAB To Invalidate Columbia Univ. DNA Patent
• Oncology Biotech Co. Secures $145M In Funding
• Insys Founder Used Data To Push Sales Reps, Ex-VP Testifies
• Quest Autodialer Suit Can't Wait On FCC, Judge Told
• FDA Commissioner Scott Gottlieb Resigns
• Weitz & Luxenberg's Quick Win In $25M Fraud Suit Challenged
• Judging A Book: Willett Reviews 'Guilty Pleasures'
• Biogen Beats Ex-Employee's Disability Bias Suit
• PTAB Rejects Challenge To Spinal Surgery Device Patent
• Bard Seeks $67M Damages Award In Vascular Port IP Case
• Calif. Justices Say Pharmacy Customers Can't Force Refunds
• Husch Blackwell Nabs FDA Practice Head From Michael Best
• Monsanto 'Opened Door' To Internal Cancer Report: Judge
• Deals Rumor Mill: Purdue Pharma, Cision, HNA Group
• 2 Firms Guide Biogen's $877M Gene Therapy Co. Buy
• Disney Beats ERISA Suit Over Valeant Shares At 9th Circ.
• Versum Investors Try To Halt Entegris Merger, Favor Merck Bid
• International Pharma Rules Tighten Restrictions On Gifts
• SEC Emphasizes Internal Controls Over Disclosure
• Insys Investors Seek Cert. In Fentanyl Stock Drop Suit
• Women In Law Need Equal Treatment, Not Affirmative Action
• Purdue Hits Mass. AG For 'Scapegoating' Co. In Opioid Suit
• 'Biosimilar V. Biosimilar' Patent Case May Be First Of Many
• Ex-Insys Exec Moves For Mistrial After Salacious Testimony
• New DOJ Opioid Cases Highlight Importance Of Red Flags
• High Court Will Decide USPTO's Win-Or-Lose Atty Fee Rule
• DOJ Atty Warns FCA Targets On Discovery Tactics
• How Firms Can Avoid Conflicts Involving Corporate Affiliates
• Ark.'s Case For Benefits Manager Law Is Flawed, Justices Told
• Novartis Slaps J&J Unit With Psoriasis Drug False Ad Suit
• Ore. Tribe Latest To Join Opioid MDL
• Ex-Doctor Can't Undo 25-Year Prison Sentence At 3rd Circ.
• Pharma Co. Chiasma To Settle Investors' IPO Suit For $18.7M
• DiCello Levitt Expands To NY With Veteran Trial Atty At Helm
• Threat To $74B Celgene Buy About More Than Just Money
• Biotech, Blank-Check IPOs Propel 1 Firm Ahead In February
• Taxation With Representation: Kirkland, Skadden, Gibson
• Convicted NECC Pharmacists Can Make Case For Acquittal
• Specialty Pharma Co. Floats Exec. Bonuses In Ch. 11
• Deals Rumor Mill: Tata Group, Global Switch, Currenta
• Insys Was 'Up Front' With MDs About Bribes, Ex-VP Testifies
• Health Hires: Goodwin, Crowell, Akin Gump, Drinker Biddle
• Versum Rejects $6B Merck Offer, Commits To Entegris Deal
• AI Radiology Co. Investor Seeks Records In Chancery Court
• Visible Diversity Is A Sign Of Organizational Health
• UK Litigation Roundup: Here's What You Missed In London
• Syneos Health Hit With Shareholder Suit Amid SEC Probe
• Simple Secrets For Writing A Killer Brief
• A Defense Attorney's Guide To Successfully Arguing Damages